MLM Biologics Inc.
MLM Biologics Inc. is dedicated to advancing wound care through innovative solutions like the bio-ConneKt® Wound Matrix, a collagen-based product designed for effective wound closure. The company emphasizes a mission of providing more effective and economical solutions for wound healing, aligning with the Gandhian Economic Principle of 'More for Less for Many.'
Industries
Nr. of Employees
small (1-50)
MLM Biologics Inc.
606 SW 3rd Avenue, Gainesville, FL 32601
Awards
Military Prototype Advancement Initiative (MPAI)
meso-ConneKt Tissue Matrix
Funding (ceiling)
$965,251.42
Award Year
2023
Products
Stabilized Type I collagen wound matrix (shelf-stable dressing)
A reconstituted, stabilized Type I collagen biomaterial supplied as a dry, sterile wound matrix intended to support host cell infiltration, fluid absorption and tissue remodeling for a range of skin breaches.
Stabilized Type I collagen wound matrix (shelf-stable dressing)
A reconstituted, stabilized Type I collagen biomaterial supplied as a dry, sterile wound matrix intended to support host cell infiltration, fluid absorption and tissue remodeling for a range of skin breaches.
Expertise Areas
- Wound care product development
- Biomaterials processing and scaffold design
- Medical device manufacturing (ISO 13485)
- Regulatory submissions and reimbursement strategy
Key Technologies
- Type I collagen scaffold
- Porous hydrophilic biomaterial scaffolds
- Stabilized collagen processing
- Terminal sterilization (SAL 10^-6)
Key People
Dr. Chandra Nataraj
CEO, CTO
Mr. Ken Harvey
President
Mr. Richard Robinson
Vice President
Mr. Deep Patel
Manager
Dr. Chandra Nataraj
CEO, CTO
Mr. Ken Harvey
President
Mr. Richard Robinson
Vice President
Mr. Deep Patel
Manager
News & Updates
On December 1st, 2023, it was announced that BioWound Solutions has acquired the exclusive sales and marketing rights to MLM Biologic’s bio-Connekt® Wound Matrix in the United States and its territories.
MLM Biologics, Inc. is awarded almost $1.5 million by the U.S. Army Medical Research and Development Command (USAMRDC) to develop a device to prevent infection in battlefield wounds.
MLM Biologics received ISO 13485 Certification for its facility, ensuring high-quality management standards in the production of medical devices.
MLM Biologics received 510(k) clearance from the US FDA for bio-ConneKt® Wound Matrix, allowing it to be marketed as a medical device.
On December 1st, 2023, it was announced that BioWound Solutions has acquired the exclusive sales and marketing rights to MLM Biologic’s bio-Connekt® Wound Matrix in the United States and its territories.
MLM Biologics, Inc. is awarded almost $1.5 million by the U.S. Army Medical Research and Development Command (USAMRDC) to develop a device to prevent infection in battlefield wounds.
MLM Biologics received ISO 13485 Certification for its facility, ensuring high-quality management standards in the production of medical devices.
MLM Biologics received 510(k) clearance from the US FDA for bio-ConneKt® Wound Matrix, allowing it to be marketed as a medical device.